Model-based inference of neutralizing antibody avidities against influenza virus

Janina Linnik^{1,2}, Mohammedyaseen Syedbasha³, Yvonne Hollenstein³,
Jörg Halter⁴, Adrian Egli^{3,5,*}, Jörg Stelling^{1,2,*}

¹ Department of Biosystems Science and Engineering, ETH Zurich, Basel, Switzerland

² Swiss Institute for Bioinformatics, Basel, Switzerland

³ Department of Biomedicine, University of Basel, Basel, Switzerland

⁴ Division of Hematology, University Hospital of Basel, Basel, Switzerland

⁵ Division of Clinical Bacteriology and Mycology, University Hospital of Basel, Basel, Switzerland

* Correspondence to: adrian.egli@usb.ch or joerg.stelling@bsse.ethz.ch

To assess the response to vaccination, quantity (concentration) and quality (avidity) of neutralizing antibodies are the most important parameters. Specifically, an increase in avidity indicates germinal center formation, which is required for establishing long-term protection. For influenza, the classical hemagglutination inhibition (HI) assay, however, quantifies a combination of both and to separately determine avidity requires high experimental effort. Here, we present a biophysical model that infers neutralizing IgG avidities from HI titers and IgG concentrations. We applied our model to infer IgG avidities against the pandemic 2009 H1N1 influenza virus in vaccinated hematopoietic stem cell transplantation patients (n = 45) and validated our results with independent avidity measurements. The model predicted that increased IgG concentrations mainly contribute to observed HI titer increases and that immunosuppressive treatment is associated with lower baseline avidities. Because the model requires only easy-to-establish measurements as inputs, we anticipate that it will help to disentangle causes for poor vaccination outcomes also in larger vaccine studies.

Introduction

- 1 To prevent influenza epidemics, it is crucial to annually develop effective vaccines against circu-
- 2 lating influenza strains. To assess vaccine efficacy, hemagglutination inhibition (HI) titers are
- 3 traditionally used as a surrogate for the influenza-neutralization capacity of vaccine-induced

antibodies in serum (Palache et al., 2003; Benoit et al., 2015). The HI assay makes use of the phenomenon that influenza viruses can bind with its surface receptor hemagglutinin (HA) to red blood cells (RBCs) and thereby cross-link RBCs to macroscopic cell aggregates in a process called hemagglutination (Hirst, 1941). In the presence of influenza-binding antibodies that block RBC binding sites, hemagglutination is inhibited. This allows quantifying the neutralization capacity of serum antibodies: the highest serum dilution that fully inhibits hemagglutination is determined, and the reciprocal of this dilution is reported as the HI titer (WHO, 2002).

The HI titer measures a combination of both antibody concentration and avidity, where avidity quantifies the overall strength of a multivalent antibody binding to hemagglutinin epitopes involved in virus-RBC interaction (neutralizing binding). When assessing vaccine response, however, it is important to distinguish between antibody concentration and avidity. In particular, no increase in avidity following vaccination indicates a hampered formation of germinal centers (GCs) where B cells undergo affinity maturation and proliferate to memory B cells or to long-lived B cells, providing long-term protection (Berek et al., 1991; Shlomchik and Weisel, 2012; De Silva and Klein, 2015).

Unfortunately, avidity measurements of serum antibodies are time-consuming and costly. In general, these measurements require long incubation times because antibodies dissociate slowly from their respective antigens. Commonly used techniques are surface plasmon resonance (SPR) and elution experiments with chaotropic agents (such as urea) based on enzyme-linked immunosorbent assays (ELISAs). While SPR experiments require special equipment and long calibration, elution assays are very sensitive to experimental conditions, and the optimal protocol might vary substantially for different antigens or even serum samples (Underwood, 1993; Olsson et al., 2019).

In comparison, measurements of HI titers and influenza-specific serum IgG concentrations are faster to establish and simpler to perform (Kaufmann et al., 2017). HI assays are considered the gold standard and routinely performed in vaccine studies; they proved to be fast, cheap, and reliable. IgG concentrations can be determined in standardized ELISA experiments. These are suitable for large-scale serological studies because they can be fully automated and yield highly reproducible results. Therefore, estimation of avidities from HI titers and IgG concentrations would facilitate influenza vaccine studies in larger populations.

Here, we present a biophysical model of the HI assay that mechanistically describes the relationship of IgG concentration and avidity to HI titer. The model enables the inference of neutralizing IgG avidities from HI titers and ELISA-detected IgG concentrations. We applied it to vaccinated hematopoietic stem cell transplantation (HSCT) patients, focusing on IgG antibodies specific to pandemic influenza A/California/7/2009 (H1N1pmd09). Despite available vaccines, the case fatality rate for influenza infection is 17–29% in these patients (Kunisaki and Janoff, 2009). Because HSCT patients are commonly immunocompromised due to the post-transplant immune reconstitution and immunosuppressive treatment against graft rejection, and patients with low

antibody avidities are likely to be at high risk for fatal infections, we investigated the association of inferred avidities with three indicators of immunocompromised status, namely first two years post transplantation, intake of immunosuppressive drugs, and chronic graft-versus-host disease (cGVHD) (Brunette et al., 2015). Our model detected that immunosuppressive treatment is associated with lower baseline avidities, but we did not detect a significant association with cGVHD or the time after transplantation. In addition, our model suggests that vaccination induced affinity maturation of neutralizing antibodies in only a few patients.

Results

Model of the hemagglutination inhibition (HI) assay

We combined and extended existing models of antibody-virus interaction (Groth, 1963) and cell-cell agglutination (Dolgosheina et al., 1992) to a model that mechanistically captures the key processes of the HI assay (**Figure 1**). The HI assay is performed in three consecutive steps (WHO, 2002): (i) Serial dilution of patient serum and 30 min incubation with influenza virus, (ii) addition of RBCs followed by 30 min incubation, and (iii) determination of the HI titer based on the presence or absence of hemagglutination inhibition in each serum dilution (**Figure 1**, top). We represent these steps separately: the model output of one step serves as input for subsequent steps (**Figure 1**, bottom).

Step 1 (binding of antibodies to virus): We modeled the binding of IgG antibodies to virus hemagglutinin (HA) as a diffusion-controlled reversible reaction between IgG molecules and virus particles (see **Methods** for all details). Each homotrimeric HA receptor has three identical binding sites for monoclonal IgG, but we assume that one HA trimer accommodates at most one IgG molecule due to steric hindrance (Taylor et al., 1987; Pountourios et al., 1990; Otterstrom et al., 2014). Serum contains a mixture of polyclonal IgG antibodies. Thus, after the addition of influenza virus to serum, HA-specific IgG clones form a mixture of IgG-HA complexes according to their individual dissociation constants (avidities). We assume that any other interactions are negligible because serum samples are pretreated with proteases to limit unspecific binding. Without information on the individual concentrations or avidities of each IgG clone, we consider the total concentration of HA-specific IgG and the apparent dissociation constant K_D^{app} . This constant is proportional to the ratio of free HA-specific IgG molecules over all formed IgG-HA complexes at equilibrium. Importantly, the inverse $1/K_D^{\text{app}}$ can be interpreted as the apparent avidity of HA-specific IgG in serum. We compute the fraction of antibody-bound virus at binding equilibrium for each serum dilution (**Figure 1**, left) as input for step 2 because 30 min incubation suffices to reach binding equilibrium.

Step 2 (hemagglutination): When RBCs are added, virus particles bind reversibly with free HA binding sites to sialic acid (SA) linked receptors on RBCs. We assume that IgG antibodies and SA-linked receptors do not compete for HA binding sites because the affinity of SA

Figure 1. Overview of the hemagglutination inhibition (HI) assay (top) and illustrative simulation results (bottom). First step: patient serum is serially diluted and incubated with a constant amount of influenza virus. The model computes the amount of antibody-bound viral hemagglutinin (HA) for each serum dilution. Second step: red blood cells (RBCs) are added to each dilution and virus particles with free HA binding sites cross-link RBCs to cell aggregates. The model predicts a switch-like increase in agglutinated RBCs with decreasing antibody concentration. Thirds step: the plate is tilted by 90 degrees to detect full hemagglutination inhibition. If none/few RBCs are agglutinated, sedimented RBCs flow down to the rim. By definition, those wells show full hemagglutination inhibition. The reciprocal of the maximal inhibitory dilution is the HI titer. We classify our simulation results into inhibition and no inhibition by setting a threshold at 25% hemagglutination. Simulation results show median and interquartile range indicating the uncertainty due to experimental conditions (RBC concentration, virus concentration, readout time) and model parameters (summarized in **Table 1**) for an IgG serum concentration of 25 nM (4 µg/mL) and $K_D^{\text{app}} = 0.1$ nM.

to HA is in the mM range (Sauter et al., 1989, 1992; Weinhold and Knowles, 1992), far below the affinity of HA-specific IgGs in the nM range (Lee et al., 2016). The tight binding of the virus to RBCs results from binding multiple SA moieties simultaneously (Takemoto et al., 1996). The virus-RBC interactions will eventually induce hemagglutination. We model it as a coagulation process (Von Smoluchowski, 1917), where RBCs stick together whenever they collide such that virus particles can cross-link them. Only when a free SA-linked receptor on an RBC meets a free HA on a virus particle that is simultaneously bound to another RBC, the collision leads to a successful cross-link. We define a degree of hemagglutination that takes the value 0% without any hemagglutination (not a single cross-link), and 100% when all RBCs form a single aggregate. The model predicts a switch-like increase in the degree of hemagglutination with decreasing antibody concentration, consistent with the experimentally observed switch-like behavior of the assay (**Figure 1**, middle).

Step 3 (determination of HI titer): After another 30 min incubation, each serum dilution is inspected for hemagglutination inhibition, and the reciprocal of the maximal dilution that shows full inhibition is the HI titer (**Figure 1**, right). To model this binary decision (inhibition or no inhibition), we classify the outcome by setting a threshold at 25% hemagglutination because we define 50% hemagglutination as partial inhibition and our model predicts for ≥ 1 HA unit virus a hemagglutination degree of $\geq 75\%$. By definition, this is interpreted as full inhibition (**Supplementary Figure S1**), suggesting that differences in hemagglutination degree below 25% or above 75% cannot be distinguished by eye.

To make the model specific for influenza H1N1pdm09, we extracted parameters from literature for IgG antibodies, the virus strain, and chicken RBCs (**Table 1**). In addition, we established the agglutination rate parameter from experiments with reference serum (see **Methods**). The model thereby establishes a quantitative relationship between neutralizing IgG concentration, HI titer, and avidity. Here, avidity is defined as the inverse of the apparent dissociation constant of the IgG-hemagglutinin complex, $1/K_D^{\text{app}}$: the lower the K_D^{app} value, the tighter the binding and thus the higher the avidity.

The model quantitatively relates IgG concentration, avidity, and HI titer

To infer antibody avidities accurately, the model needs to be sensitive to the experimental data used as inputs. However, it should not be sensitive to other experimental factors and uncertainties in model parameters. To evaluate the model in this respect, we used Sobol sensitivity analysis (Saltelli et al., 2004), which attributes variance in model output (here: hemagglutination degree) to the individual model input factors. The more influential the input factor is, the higher is its contribution to the variance in hemagglutination degree. We considered the ranges for all model input factors summarized in **Table 1**. In particular, for IgG concentration and avidity the ranges match the experimentally observed ranges for H1N1pdm09-specific IgG after vaccination in adults, which are approximately 0 – 420 $\mu\text{g/mL}$ serum IgG (Eidem et al.,

Table 1. Model parameters and variables. Abbreviations are: IgG, Immunoglobulin G; RBC, red blood cell; HA, hemagglutinin; HAU, HA unit; SA, sialic acid.

Description	Symbol	Value	Distribution in sensitivity analysis	Reference
Serum IgG concentration	A_0	Sample-specific	Unif(0, 2800) nM (0 - 420 $\mu\text{g/mL}$)	Eidem et al. (2015)
Apparent IgG dissociation constant	K_D^{app}	Sample-specific	Unif(0.001, 300) nM	Lee et al. (2016)
Initial virus concentration	V_0	$1.3 \cdot 10^{-4}$ nM (4 HAU)	Unif($0.9 \cdot 10^{-4}$, $2.3 \cdot 10^{-4}$) nM (3 - 7 HAU)	WHO (2002)
Initial RBC concentration	RBC_0	$3.1 \cdot 10^{-5}$ nM	Unif($1.6 \cdot 10^{-5}$, $6.3 \cdot 10^{-5}$) nM	WHO (2002)
Number of HA receptors per virus	r	400	Discrete Unif(300,500)	Ruigrok et al. (1984); Harris et al. (2013)
Number of epitopes per HA receptor	e	3	Fixed at 3	Wilson et al. (1981); Jackson et al. (1991)
Number of shaded epitopes per bound IgG	e^*	3	Bernoulli(0.5) with $e^* \in \{3, 6\}$	Otterstrom et al. (2014)
Number of SA receptors per RBC	b	$4.5 \cdot 10^5$	Discrete Unif($4 \cdot 10^5$, $5 \cdot 10^5$)	Aich et al. (2011); Aoki (2017)
Number of shaded SA receptors per bound virus	b^*	34	Sampled from model	See Methods
SA-HA association rate constant	$k_{\text{ass}}^{\text{RBC}}$	$2 \cdot 10^{-6} \text{ s}^{-1}$	$\mathcal{N}(2 \cdot 10^{-6}, (0.4 \cdot 10^{-6})^2) \text{ s}^{-1}$	Takemoto et al. (1996)
SA-HA dissociation rate constant	$k_{\text{diss}}^{\text{RBC}}$	$2 \cdot 10^{-4} \text{ nM}^{-1} \text{ s}^{-1}$	$\mathcal{N}(2 \cdot 10^{-4}, (0.4 \cdot 10^{-4})^2) \text{ nM}^{-1} \text{ s}^{-1}$	Takemoto et al. (1996)
RBC agglutination rate constant	k_{agg}	$2 \cdot 10^6 \text{ s}^{-1}$	Unif($0.4 \cdot 10^6$, $13 \cdot 10^6$) s^{-1}	Estimated from data

Figure 2. Model sensitivity and resolution of the hemagglutination inhibition assay for influenza H1N1pdm09. (a) Sensitivity analysis using Sobol indices. First-order effects show only the linear contribution to the total variance in hemagglutination degree (they sum up to 1), whereas total effects consider also interactions (see **Methods** for details). (b) Predicted degree of hemagglutination for different IgG concentrations and apparent dissociation constants K_D^{app} . The red box indicates the usual assay range, bounded by the biological range of $K_D^{app} = 0.001 - 100$ nM, and the gray dashed line indicates $K_D^{app} = 0.03$ nM. (c) Predicted HI titers for the biological range of influenza-specific serum IgG and K_D^{app} . Colored areas correspond to titers shown on top.

2015) and $K_D^{app} = 0.001 - 300$ nM (Lee et al., 2016). For experimental conditions, we aimed to generously cover experimental variability (0.375 – 1.5% (v/v) RBC suspension, 3 – 7 HA units influenza virus and a readout time of 30 to 45 min). For model parameters, we considered measurement uncertainty and biological variability as described in the literature.

Sensitivity analysis showed that avidity and serum IgG concentration are the most influential factors for the model's output (**Figure 2a**). Variability in RBC and virus concentration, as well as in readout time, contribute very little to the total variance. The model is also robust to uncertainty in all model parameters except for the kinetic agglutination rate of RBCs, which we varied within the 95% highest probability density interval estimated from our calibration data (see **Methods**). Other relevant factors were the ability of IgG to bind two HA receptors simultaneously and the number of RBC receptors that are covered by one bound virion. Hence, the model's predictions are dominated by the measured input quantities, despite uncertainties on mechanisms and parameters.

According to the degree of hemagglutination, the model predicts a clear separation between

129 inhibition and no inhibition — partial inhibition occurs only within a small range of IgG con-
 130 centration and avidity (**Figure 2b**). Thus, the well-known binary nature of the assay is captured.
 131 Using an initial virus concentration of 4 HA units as defined by WHO ensures both high sen-
 132 sitivity and robustness, whereas 8 HA units or more increase robustness but lower sensitivity
 133 (**Supplementary Figure S1e**). In addition, the model predicts a yet unknown property of the
 134 HI assay within its range. For avidities $K_D^{\text{app}} \geq 0.03$ nM, hemagglutination quantifies a combi-
 135 nation of IgG concentration and avidity, but for very high avidities $K_D^{\text{app}} < 0.03$ nM, the assay
 136 only detects changes in IgG concentration (**Figure 2b**).

137 Correspondingly, within the linear range for $K_D^{\text{app}} \geq 0.03$ nM, a doubling in IgG concentra-
 138 tion or avidity results in a doubling of the predicted HI titer (**Figure 2c**). In other words, a
 139 two-times lower antibody avidity can be compensated by a two-times higher antibody concen-
 140 tration. However, this only applies to the linear range. The exact relationship depends on the
 141 considered avidity and concentration ranges (**Figure 2c**). For instance, in our experimental
 142 setup, where serum samples were 1:8 prediluted and then two-fold serially diluted, the minimal
 143 concentration to reach seroprotection (HI titer ≥ 40) with an IgG avidity of $K_D^{\text{app}} = 1$ nM is an
 144 IgG serum concentration of 104 nM (16 $\mu\text{g/mL}$), whereas for $K_D^{\text{app}} = 10$ nM, the minimal sero-
 145 protective IgG concentration increases to 1018 nM (153 $\mu\text{g/mL}$). These values correspond to
 146 approximately 0.1 – 10% of total serum IgG (Gonzalez-Quintela et al., 2008) and lie within the
 147 observed range for influenza-specific serum IgG concentrations in seroprotected healthy adults
 148 (Eidem et al., 2015). The model also suggests why HI titers above 8192 ($= 13$ in $\log_2$) are rarely
 149 observed. Even for a high serum IgG concentration of 1000 nM (150 $\mu\text{g/mL}$), such high titers
 150 require antibody avidities in the fM range, but influenza-specific monoclonal antibody affinities
 151 in vaccinated healthy adults lie in the nM range (Lee et al., 2016). Therefore, we conclude that
 152 the model yields robust predictions in the applicable assay range, and reveals new quantitative
 153 aspects of the HI assay.

154 Inference of neutralizing antibody avidities in HSCT patients

155 Next, we applied our model to infer avidities from ELISA-detected serum IgG concentrations
 156 and HI titers in HSCT patients (patient characteristics are summarized in **Table 2**). Specifically,
 157 we used a Bayesian approach that accounts for uncertainties due to ELISA measurement error
 158 and discretization in HI titers (see **Methods** for details). Model parameters were fixed for all
 159 serum samples (**Table 1**), assuming that differences in HI titer arise mostly from differences in
 160 serum IgG and avidity as suggested by our sensitivity analysis (**Figure 2a**).

161 Measurements were available from 45 patients at five time points before (d0) and after (d7, d30,
 162 d60, d180) the first vaccination with 221 serum samples in total. Patients received two doses
 163 of non-adjuvanted trivalent seasonal influenza vaccine on d0 and d30 (see **Methods**). HI titers
 164 and IgG concentrations were significantly correlated (Kendall's $\tau = 0.69$, $p < 10^{-15}$, rank
 165 correlation for ordinal data; **Figure 3a**). However, especially moderate HI titer values of 32

and 64 ($\log_2$ HI titer 5 and 6) showed a large spread in serum IgG, indicating variable antibody avidities.

For serum samples with HI titers below assay resolution (HI titer < 8), we could only infer an upper bound for the avidity (it could be lower, but not higher). This affected 23 serum samples from seven patients. Analogously, for serum samples with $K_D^{\text{app}} \leq 0.03$ nM, we could, in principle, only report a lower bound, but all inferred avidities for our patient cohort exceeded this threshold. In 24 samples, inferred K_D^{app} values showed very large uncertainty (approximately $\pm 100\%$) due to large measurement error in ELISA measurements; we excluded these samples from further analysis. In the remaining samples, the average uncertainty in K_D^{app} values was $\pm 27\%$ (interquartile range, IQR 25 – 28%). This mostly results from discretized HI titers because the average uncertainty in ELISA measurements was only $\pm 10\%$, as normally observed for ELISA. In addition, posterior distributions of inferred avidities were log-normally distributed (**Supplementary Figure S2**), indicating that we computed meaningful credibility intervals by sampling (see **Methods**).

In summary, we were able to reliably infer 197 avidities from in total 43 patients (89% of analyzed samples). Inferred avidities ranged from $K_D^{\text{app}} = 0.08$ nM to ≥ 37 nM (upper bound), with a median of 1.7 nM and IQR 0.9 – 2.5 nM, thus covering almost the full biological range (see **Figure 2c**). Inferred avidities and HI titers were significantly correlated (Kendall's $\tau = 0.56$, $P < 10^{-15}$), although the correlation was weaker than for IgG concentrations (**Figure 3a**).

Inferred avidities correlate with experimentally determined avidities

To validate our model, we measured serum IgG avidities specific to H1N1pmd09 in 59 serum samples from a total of 12 HSCT patients. We performed ELISA-based elution assays that quantify the fraction of IgG remaining bound after 3h incubation with 4M urea, yielding a measure for the overall binding strength of serum IgG to H1N1pmd09 in the form of an index between 0 (low avidity) and 1 (high avidity). The inferred apparent dissociation constants K_D^{app} and the experimentally determined avidity indices were significantly correlated (Pearson $\rho = 0.54$, $p < 10^{-4}$, **Figure 3b**). We detected one outlier patient (standardized residuals ≈ 3) whose serum did not show HI activity at any time point (**Figure 3b**), suggesting that the ELISA assay detected non-neutralizing IgG in this patient.

Next, we asked if the inferred avidities could help explain patient-specific responses to vaccination over time. Given the uncertainty in inferred K_D^{app} -values due to discretized HI titer observations, we could detect fold changes in avidity of approximately > 1.5 or < 0.5 (except for samples below the HI assay's resolution with titer < 8). Experimental and inferred avidities indeed distinguished different types of patient responses, for example, where both IgG concentration and avidity increased after vaccination (patient 1 in **Figure 3c**) or where an increase in HI titer was mostly explained by an increase in IgG concentration (patient 2). Moreover, we

Figure 3. Inference of antibody avidities in HSCT patients. (a) ELISA-detected anti-H1N1pmd09 serum IgG concentration, HI titers and corresponding inferred apparent dissociation constants K_D^{app} from 197 serum samples from 43 HSCT patients. The dashed line indicates the seroprotection threshold (HI titer ≥ 40). (b) Correlation of inferred and experimentally determined avidities in 59 serum samples from 12 HSCT patients (Pearson $\rho = 0.54$, 95% CI = [0.31, 0.70]). Data show mean and standard deviation for avidity indices from two experiments (each performed in duplicates) and the maximum a posteriori (MAP) estimates and uncertainty range due to discretized HI titer measurements and ELISA measurement error for inferred dissociation constants K_D^{app} (see **Methods** for details on inference). Avidity indices correspond to the fraction of H1N1pmd09-specific serum IgG remaining bound after 4M urea treatment. Patient 11 was identified as an outlier, probably because ELISA detected non-neutralizing IgG; the patient showed no HI activity at any time point. (c) Example patients with different types of responses to vaccination. In patient 3, we detected an increase in non-neutralizing IgG on d30. The predicted HI titer for the observed increase in IgG (shown in grey) is twice as high as the actually observed titer (green). For all 12 patients with experimentally determined avidities see **Supplementary Figure S3**.

identified one patient that produced non-neutralizing IgG upon vaccination (patient 3 in **Figure 3c**): In this patient, the ELISA detected an increase in IgG concentration that leads to HI titer doubling according to our model predictions. However, the HI titer did not increase at any time point (**Figure 3c**), suggesting that the ELISA-detected IgGs had no HI activity (were non-neutralizing). The inferred apparent dissociation constant K_D^{app} refers to neutralizing IgG-virus interactions only, and its value is biased towards lower avidity if the measured IgG concentration also includes non-neutralizing IgGs. Nevertheless — in contrast to patient 11 who did not show HI activity at any time point (**Figure 3b**) — the inferred avidities for patient 3 approximately mirrored the experimentally determined avidity indices, probably because this patient showed high HI titer and serum IgG levels before vaccination and only a small increase in non-neutralizing IgGs after vaccination, indicating that previously acquired neutralizing IgGs dominated the avidity measurements (**Figure 3c**). Thus, apparent serum avidities inferred by our model-based approach were in good accordance with experimentally determined avidity indices. However, as one would expect, if non-neutralizing IgG dominates in serum, the results are not directly comparable because the inferred avidity refers to neutralizing IgG with HI activity.

Detection of vaccine-induced affinity maturation in HSCT patients

Next, we compared the vaccine-induced increase in inferred avidities in all investigated HSCT patients and identified candidates for successful GC formation and affinity maturation (**Figure 4**). Since the establishment of GCs takes approximately seven days (De Silva and Klein, 2015), we considered an increase in IgG concentration and avidity on d30 or d60 as indicative for GC formation (patients were vaccinated on d0 and d30; see **Methods**).

The response characteristics of the patient cohort are shown in **Figure 4a**. Taking uncertainty in inferred K_D^{app} values into account, eight patients showed a detectable increase in avidity on d30 and/or d60, of which only one showed no increase in serum IgG (**Figure 4b**). This suggests that vaccination induced GC formation and affinity maturation in seven patients (including patient 1 in **Figure 3c**), although serum avidity returned back to baseline on d180 in most of the patients, suggesting that vaccination failed to induce a sustained production of high-avidity antibodies by long-lived plasma cells. In two out of seven patients, avidity increased already on d7, suggesting that reactivated memory B cells released high-avidity IgG. Over all patients showing a detectable increase in avidity at any time point after vaccination ($n = 11$), we observed a time-dependent increase with the largest increase on d60, i.e. after the booster dose (**Figure 4c**). Of these patients, only one showed an increase in avidity on d7 but not at later time points and two patients only on d180. In conclusion, most patients showed affinity maturation dynamics consistent with our understanding of GC dynamics (De Silva and Klein, 2015).

We could not detect a significant increase in avidity in 24 patients, although 15/24 patients showed an increase in serum IgG on d30 or d60 (such as patient 2 in **Figure 3c**). We identified

Figure 4. Vaccine response to influenza H1N1pmd09 in HSCT patients. (a) Patients were vaccinated on d0 and d30 with a non-adjuvanted trivalent influenza vaccine. Serum IgG was measured by ELISA with whole-virus coating (see **Methods**). (b) Fold changes in HI titer, serum IgG and avidity ($1/K_D^{app}$) in all patients with a detectable increase in inferred avidity on d30 and/or d60. (c) Comparison of inferred avidities between patients with a detectable increase in avidity at any time point after vaccination (left), patients with no detectable increase (middle), and patients with a detectable increase in non-neutralizing IgG (right). (d) Estimated effects of criteria for compromised immune response according to the CDC. Effects were estimated from multiple regression on log2-transformed values controlling for sex and age (model for continuous data for serum IgG and avidity, model for ordinal data for HI titers, see **Methods**). Time after HSCT was encoded as a binary variable (1 for HSCT $\leq$ 2 years and 0 for HSCT $>$ 2 years). Immunosuppression grade and cGVHD grade ranging from 0 (no immunosuppression/cGVHD) to 3 (severe immunosuppression/cGVHD) were encoded as ordered categorical variables with grade 0 as reference. P-values $<$ 0.05 were considered significant.

239 six patients as non-neutralizing IgG producers, including patient 3 in **Figure 3c**. These patients
240 showed no increase in HI titer despite showing an increase in IgG concentration that resulted in
241 a significant bias towards lower avidities (**Supplementary Figure S4a**). We excluded 4/45 pa-
242 tients as they showed too large measurement uncertainty in ELISA-detected IgG concentrations
243 on several time points (see above).

244 In summary, although 30 patients showed an increase in serum IgG on d30 and/or d60, only
245 7/30 patients (23%) are candidates for vaccine-induced affinity maturation, and 6/30 patients
246 (20%) showed vaccine-induced production of non-neutralizing IgG.

247 **Association with criteria for compromised immune response**

248 Finally, we investigated differences in inferred avidity, serum IgG concentration, and HI titer
249 between different patient groups. We considered criteria for compromised immune response
250 as defined by CDC, which are known to be associated with immune cell proliferation, affin-
251 ity maturation and antibody production (Brunette et al., 2015; Ogonek et al., 2016): (i) first
252 two years post transplantation (time post HSCT ≤ 2 years), (ii) intake of immunosuppressive
253 drugs quantified by immunosuppression grade ranging from 0 (no immunosuppression) to 3
254 (severe immunosuppression), and (iii) chronic graft-versus-host disease (cGVHD) quantified
255 by cGVHD grade between 0 (no cGVHD) and 3 (severe cGVHD) according to NIH criteria
256 (Filipovich et al., 2005). We investigated effects on baseline (i.e. levels before vaccination) and
257 response (relative increase from baseline) in a multivariable linear regression analysis with the
258 three criteria as explanatory variables and additionally controlling for sex and age. Regression
259 was performed on log2-transformed values using models for continuous data for serum IgG
260 and avidity, whereas HI titers were treated as ordinal data (see **Methods**). When analyzing
261 the vaccine-induced increase in avidity, we excluded non-neutralizing IgG responders ($n = 6$,
262 **Figure 4c**) because their biased inferred avidities are not indicative of affinity maturation.

263 Early transplant patients (time post HSCT ≤ 2 years) showed significantly lower serum IgG
264 (-1.92 ± 0.46 , $P = 1.8 \cdot 10^{-4}$) and HI titer baseline levels (log odds ratio -0.96 ± 0.25 ,
265 $P = 1.2 \cdot 10^{-4}$) than patients with HSCT > 2 years (**Figure 4d**). At the time of this study, the
266 annual influenza vaccine contained H1N1pmd09 already for five years. Therefore, it is likely
267 that patients with HSCT > 2 years acquired durable H1N1pmd09-neutralizing antibodies in
268 previous seasons. Yet, early transplant patients did not show significantly different baseline
269 avidities compared to patients with HSCT > 2 years (0.36 ± 0.45 , $P = 0.43$), potentially
270 because previous vaccinations did not induce long-term production of high-avidity antibodies.
271 This is consistent with some patient observations in the present season (**Figure 4b**).

272 Most patients in our cohort under immunosuppression received cell division inhibitors such as
273 prednisone or mycophenolate mofetil (MMF) and calcineurin inhibitors such as tacrolimus or
274 cyclosporine A that lower T cell activity, while few patients received rituximab, an anti-CD20
275 antibody that leads to B-cell depletion (**Table 2**). Immunosuppression grade was associated

with lower serum IgG baseline levels, although not significantly (-0.36 ± 0.19 , $P = 0.07$), and with significantly lower baseline avidities (-0.58 ± 0.19 , $P = 4.0 \cdot 10^{-3}$) and baseline titers (log odds ratio -0.65 ± 0.11 , $P = 3.1 \cdot 10^{-9}$, **Figure 4d**). Since we did not know the patients' medical history, we could not investigate whether the low baseline levels are explained by immunosuppressive drug treatment or an underlying disease during a former encounter with H1N1pmd09. For instance, patients might have suffered from GVHD in previous seasons, which required treatment with immunosuppressive drugs. In the current season, we could not detect any effects on the vaccine-induced increase in serum IgG or avidity, probably due to lack of power. We also did not detect significant effects of cGVHD on avidity or serum IgG, but we found a positive effect on HI baseline titers (log odds ratio 0.43 ± 0.11 , $P = 6.2 \cdot 10^{-5}$).

In conclusion, the time after transplantation showed a significant, positive effect on baseline levels in serum IgG and HI titers but no significant effect on baseline avidity. Instead, patients under immunosuppression showed significantly lower baseline avidities with an estimated effect size of approximately -0.6 ± 0.2 per immunosuppression grade (for log2-transformed $1/K_D^{\text{app}}$ values). This means, that in our HSCT patient population, patients with immunosuppression grade 2 showed approximately two-fold lower baseline avidities than patients without immunosuppression, while patients with immunosuppression grade 3 show three- to four-fold lower baseline avidities (**Supplementary Figure S5**). We did not detect significant differences in the vaccine-induced increase in serum IgG or avidity, potentially because the number of responders in the investigated HSCT population was too low (only 13 patients showed seroconversion).

Discussion

The HI assay is a well-established gold standard method, and yet, little is known on the relationship between HI titer, serum antibody concentration, and avidity. Mathematical models of cell agglutination by antibody cross-linking have been previously reported (Ming et al., 1965; Dolgosheina et al., 1992) and applied to guide the design of immunoassays (Kylilis et al., 2019). Here, we present an extension to a system of three components consisting of antibodies, viruses, and cells. Our model captures known properties of the HI assay and provides a biophysical explanation for why the HI assay has become the gold standard in serological studies. First, the assay is equally sensitive to both antibody concentration and avidity. Only for extremely high avidities ($K_D^{\text{app}} \leq 0.03$ nM), it detects only changes in concentrations. Second, the assay is robust to pipetting errors or other experimental variabilities in RBC and virus concentration.

Model development required simplifying assumptions that necessarily limit the model's applicability. For example, we neglected IgM antibodies because IgMs show lower serum concentration than IgGs (Gonzalez-Quintela et al., 2008). When IgM concentration is high while IgG concentration is low, for example, on d7 after vaccination in a naive subject, modeling the contribution of IgM to the HI titer may be necessary. However, the model can describe mono- and

312 bivalent IgG binding, and it can distinguish bivalent binding to the same HA receptor from bi-
 313 valent binding to two different HA receptors, resulting in lower K_D^{app} compared to monovalent
 314 binding (Edwards and Dimmock, 2000; Williams et al., 2018). Note also that we assume that
 315 the simultaneous binding of HA receptors on two different virus particles is rare under HI assay
 316 conditions and thus negligible.

317 Regarding our experimental assays, we note that most influenza-specific IgG antibodies bind to
 318 the immunodominant HA globular domain (part of HA1) that harbors the SA binding site and
 319 attaches the virus to host cells (Wilson et al., 1981; Gerhard et al., 1981). Although we used
 320 whole-virus for ELISA coating, we observed a similar correlation between ELISA-detected
 321 serum IgG and HI titers as previous studies for HA and HA1 coating (Li et al., 2014; Trombetta
 322 et al., 2018). This is in line with studies on immunodominance showing that antibody response
 323 to influenza is dominated by HA-specific neutralizing IgG, and the HA globular domain is
 324 favored over the HA stalk domain, neuraminidase or other proteins on influenza (Altman et al.,
 325 2015; Angeletti et al., 2017). However, detection of both neutralizing and non-neutralizing IgG
 326 can bias our results towards lower avidities; this possibility could be evaluated with surface
 327 plasmon resonance or calorimetry measurements.

328 The model allows the inference of serum avidities from ELISA-detected IgG concentrations and
 329 HI titers, which are simpler, faster, and cheaper to measure than antibody avidities, especially
 330 in larger populations. In our experimental setup where HI titers were determined in two-fold
 331 serial dilutions, we were able to estimate neutralizing serum avidities with a precision of ap-
 332 proximately $\pm 25 - 30\%$. A limitation of our approach is that we cannot distinguish whether
 333 HI titers below assay resolution (HI titer < 8) correspond to non-neutralizing IgG (which could
 334 potentially have high avidity but not to HA) or to neutralizing IgG below assay resolution (with
 335 low avidity or low concentration).

336 We inferred serum avidities for our HSCT patient cohort because serum avidities serve as mark-
 337 ers for GC formation and affinity maturation in vaccine studies in general (Khurana et al., 2011,
 338 2012; Eidem et al., 2015; Khurana et al., 2019). For example, it has been shown that in response
 339 to influenza A, the average HA-specific affinity of GC B cells is correlated with the HA-specific
 340 apparent avidity of serum antibodies (Frank et al., 2015) and that avidity of serum antibodies
 341 is important for protection (Olszewska et al., 2000; Polack et al., 2003). However, it is un-
 342 known to which extent and with which dynamics influenza vaccination against H1N1pmd09
 343 induces affinity maturation in HSCT patients. Previous studies in healthy adults vaccinated
 344 against H1N1pmd09 showed that serum avidity to HA1 peaks at 21 – 28d after vaccination
 345 and decreases almost back to baseline on d180 (Eidem et al., 2015; Khurana et al., 2019). We
 346 observed a similar behavior among those HSCT patients that showed a detectable increase in
 347 avidity, although, in contrast to healthy subjects, HSCT patients received a booster dose on d30.
 348 Over all patients, we observed the largest increase in avidity on d60, suggesting that the booster
 349 dose might be important for vaccine-induced affinity maturation.

Only a few patients showed a vaccine-induced increase in avidity. This may be because the number of responders was low or because the increase was below our detection limit (fold change < 1.5). Whether poor vaccine-induced affinity maturation is responsible for the poor effectiveness of seasonal influenza vaccination is currently under debate (Ellebedy, 2018; Arevalo et al., 2020; Hoehn et al., 2021). However, we observed consistent effects: among 32 (13) patients with a vaccine-induced increase in serum IgG on d30 or d60 (seroconversion on d60), we identified only seven (five) candidates for vaccine-induced affinity maturation. Thus, vaccine-induced increases in HI titer were mostly explained by increased IgG concentrations. These results might not apply to other populations, especially because hampered affinity maturation is likely in HSCT patients (Ogonek et al., 2016). Yet, the correlation between HI titers and serum IgG in healthy adults is only slightly lower than in our population (reported 95% confidence intervals for Pearson's $\rho = [0.55, 0.67]$ for ELISA-measured IgG with H1N1pmd09-specific HA coating compared to Pearson's $\rho = [0.77, 0.87]$ for our results) (Trombetta et al., 2018), suggesting that also in healthy populations differences in HI titers are mostly explained by differences in serum IgG concentration.

Interestingly, all patients identified as non-neutralizing IgG producers showed relatively high HI titers (ranging from 32 – 1024 with a geometric mean titer of 128) and high neutralizing avidities before vaccination (**Figure 4c**). Even if we detected both neutralizing and non-neutralizing IgG on d0 in these patients, this would bias the inferred K_D^{app} values towards lower avidities, which means that the actual neutralizing baseline avidities could be even higher. This observation supports computer simulations suggesting that preexisting antibodies that mask immunodominant epitopes lead to the production of antibodies specific to less accessible epitopes (Meyer-Hermann, 2019). This might be particularly important for the generation of so called broadly neutralizing antibodies that target the membrane proximal HA stalk domain, which is less accessible but more conserved than the HA globular domain (Krammer, 2019). These antibodies show high potential *in vivo* despite poor neutralization activity *in vitro* (Krammer, 2016). Therefore, additional studies might investigate whether preexisting antibodies with high neutralizing avidities against the HA globular domain lead to the vaccine-induced production of antibodies against the HA stalk domain.

The precision of our inference approach was also sufficient to detect differences in baseline avidities between HSCT patients with and without immunosuppressive treatment. Excluding the two patients without HI activity at any time point from our analysis only slightly affects the detected association between immunosuppression grade and avidity (-0.39 ± 0.16 , $p = 0.02$). Previous studies in healthy adults showed that repeated annual vaccination against H1N1pmd09 can increase H1-specific baseline avidities (Eidem et al., 2015; Khurana et al., 2019). Patients with ongoing immunosuppression or cGVHD are recommended to receive yearly influenza vaccination (Hilgendorf et al., 2011) but in this study, we could not investigate further whether differences in baseline avidities were associated with immunosuppressive treatment at the time of vaccination, or simply with repeated annual vaccinations against H1N1pmd09.

389 Interestingly, HI titers were negatively associated with immunosuppression grade but positively
390 with cGVHD grade. Patients with cGVHD show disturbed B cell homeostasis, persistent B cell
391 activation, and elevated levels of B-cell activating factor (BAFF), which promotes survival and
392 differentiation of activated B cells (Sarantopoulos et al., 2007, 2009; Greinix et al., 2008; Jacob-
393 son et al., 2014). However, several studies reported no significant effect of cGVHD on vaccine
394 response to H1N1pmd09 (Issa et al., 2011; Engelhard et al., 2011; Gueller et al., 2011) or a
395 negative effect (Roll et al., 2012; Mohty et al., 2011). Information on the patients' vaccination
396 history, medication and disease state at the time of previous vaccinations would be required to
397 better understand this association.

398 Overall, we argue that the new analysis capabilities afforded by our biophysical model for the
399 HI assay not only generate detailed insights and hypotheses on vaccination responses in small
400 patient cohorts as here. Because the model requires only easy-to-establish measurements as
401 inputs, we anticipate that it can also refine the analysis in larger vaccine studies.

402 **Methods**

403 **Model derivation**

404 *Assay step 1: binding of antibodies to virus*

405 We model the formation of antibody-epitope complexes, denoted by C , as a diffusion-controlled
406 reaction between viruses and antibodies, following the model of antibody-virus interaction pro-
407 posed by Groth (1963). For complex formation, free antibodies, A , need to successfully collide
408 with free influenza virus particles, V . In addition, antibody-epitope complex formation de-
409 pends on the probability of epitopes being unbound, denoted by ϕ . The dynamics of complex
410 formation is thus given by:

$$\frac{dC(t)}{dt} = k_{\text{ass}} \cdot A(t) \cdot V(t) \cdot \phi(t) - k_{\text{diss}} \cdot C(t),$$

411 where k_{ass} and k_{diss} are kinetic rate constants for association and dissociation, respectively.
412 Note that some IgG antibodies bind bivalently to hemagglutinin, resulting in higher antibody
413 affinities compared to their monovalent Fab fragments due to lower macroscopic dissociation
414 rates (Edwards and Dimmock, 2000; Williams et al., 2018). This antibody valency is lumped
415 into the macroscopic dissociation constant k_{diss} .

416 The total number of epitopes is proportional to the total virus concentration V_{tot_1} (where '1'
417 indicates the first step of the assay), the average number of hemagglutinin receptors per virus, r ,
418 and the number of identical binding sites per hemagglutinin, e ($e = 3$ since hemagglutinin is a

419 homotrimer). With e^* being the number of epitopes bound or shaded by one antibody molecule,
420 the fraction of unbound epitopes is:

$$\phi(t) = \frac{e \cdot r \cdot V_{\text{tot}_1} - e^* \cdot C(t)}{e \cdot r \cdot V_{\text{tot}_1}}.$$

421 We assume that cross-linking of virus particles by antibodies is rare for the considered con-
422 centrations, such that the concentration of virus particles V remains approximately the same
423 during the experiment, i.e., $V \approx V_{\text{tot}_1}$. In addition, the mass balance for antibodies is $A_{\text{tot}_1} =$
424 $A(t) + C(t)$. Substituting into the dynamics of complex formation leads to:

$$\frac{dC(t)}{dt} = \frac{k_{\text{ass}}}{e \cdot r} \cdot [A_{\text{tot}_1} - C(t)] \cdot [e \cdot r \cdot V_{\text{tot}_1} - e^* \cdot C(t)] - k_{\text{diss}} \cdot C(t).$$

425 Since the average number of epitopes per virus particle $e \cdot r$ is constant, the dynamics is equiv-
426 alent to a reversible bimolecular reaction following mass action kinetics with apparent dissoci-
427 ation constant $K_D^{\text{app}} = e \cdot r \cdot \frac{k_{\text{diss}}}{k_{\text{ass}}}$. We assume that antibody-virus binding is fast, such that after
428 the incubation time the system is at steady-state. At steady-state, the complex concentration
429 C^{eq} fulfills

$$0 = [A_{\text{tot}_1} - C^{\text{eq}}] \cdot [e \cdot r \cdot V_{\text{tot}_1} - e^* \cdot C^{\text{eq}}] - K_D^{\text{app}} \cdot C^{\text{eq}}.$$

430 We exploit the analytic solution to this quadratic equation in C^{eq} to compute the fraction of
431 covered hemagglutinin epitopes at equilibrium, θ , defined as:

$$\theta = \frac{e^* \cdot C^{\text{eq}}}{e \cdot r \cdot V_{\text{tot}_1}}$$

to obtain:

$$\theta = \frac{erV_{\text{tot}_1} + e^* A_{\text{tot}_1} + K_D^{\text{app}}}{2erV_{\text{tot}_1}} - \frac{\sqrt{e^2 r^2 V_{\text{tot}_1}^2 + (K_D^{\text{app}})^2 + e^{*2} A_{\text{tot}_1}^2 - 2erV_{\text{tot}_1} e^* A_{\text{tot}_1} + 2K_D^{\text{app}} erV_{\text{tot}_1} + 2K_D^{\text{app}} e^* A_{\text{tot}_1}}}{2erV_{\text{tot}_1}}. \quad (1)$$

432 Assay step 2: hemagglutination

433 When RBC suspension is added to the system, two processes happen simultaneously: viruses
434 bind to SA-linked receptors on RBCs with their free hemagglutinin binding sites, and RBCs
435 stick together and form aggregates whenever they collide such that virus particles are able to
436 cross-link them.

437 For virus binding to SA-linked receptors, we assume mass-action kinetics, leading to:

$$\frac{dV(t)}{dt} = -k_{\text{ass}}^{\text{RBC}} \cdot \underbrace{(1 - \theta) \cdot r \cdot V(t)}_{\text{free virus sites}} \cdot \underbrace{[1 - \rho(t)] \cdot b \cdot \text{RBC}_{\text{tot}_2}}_{\text{free RBC sites}} + k_{\text{diss}}^{\text{RBC}} \cdot \underbrace{\frac{b}{b^*} \cdot \rho(t) \cdot \text{RBC}_{\text{tot}_2}}_{\text{bound RBC sites}}. \quad (2)$$

438 Kinetic constants for association and dissociation are denoted as $k_{\text{ass}}^{\text{RBC}}$ and $k_{\text{diss}}^{\text{RBC}}$. We assume
 439 $e = e^* = 3$ (Poumbourios et al., 1990) to define the contribution of the concentration of hemag-
 440 glutinin receptors that are not covered by antibodies (free virus sites) to the association rate.
 441 Association further depends on the amount of RBC binding sites that are not yet covered by
 442 virus, defined by the fraction of covered sites, $\rho(t)$, the average number of SA-linked surface re-
 443 ceptors each RBC carries, b , and the total concentration of RBCs in step 2 of the assay, RBC_{tot_2} .
 444 For the dissociation term, we assume that one virus particle covers on average b^* binding sites,
 445 since influenza virus particles are approximately 60-times smaller than RBCs (see below). The
 446 correction by b^* reflects the definition of the fraction of covered RBC binding sites (making the
 447 term for bound RBS sites equivalent to the concentration of bound virus, $V_{\text{tot}_2} - V(t)$):

$$\rho(t) = \frac{b^* \cdot [V_{\text{tot}_2} - V(t)]}{b \cdot RBC_{\text{tot}_2}}. \quad (3)$$

To capture RBC aggregation, let B_k denote the concentration of agglutinating particles (indi-
 vidual RBCs and RBC aggregates) consisting of k cells, with a maximum aggregate size N .
 To describe the dynamics, we use the Smoluchowski coagulation equation (Von Smoluchowski,
 1917), where the rate of agglutination is proportional to an agglutination rate constant k_{agg} and
 the number of available cross-linking sites $\rho(t)(1 - \rho(t))(1 - \theta)^2$, which is proportional to the
 number of mutual pairs of free binding sites on colliding RBCs and can be interpreted as a
 cross-linking probability:

$$\frac{dB_k(t)}{dt} = k_{\text{agg}}\rho(t)(1 - \rho(t))(1 - \theta)^2 \left(\frac{1}{2} \sum_{i+j=k} K_{ij} B_i(t) B_j(t) - B_k(t) \sum_{i=1}^N K_{ik} B_i(t) \right)$$

For the special case $K_{ij} = K_{ik} = K$, where the kernel is independent of the particle size, there
 is a simple analytical solution for the discrete size distribution of aggregates. Let $\sum_{i=1}^N B_i(t) =$
 $B_N(t)$ denote the total concentration of particles, and $B_N(t = 0) = RBC_{\text{tot}_2}$ the concentration
 of particles before agglutination. In addition, from mass conservation follows: $\sum_{k=1}^N k B_k(t) =$
 RBC_{tot_2} . Summing over all values of k then yields:

$$\begin{aligned} \frac{dB_N(t)}{dt} &= k_{\text{agg}}\rho(t)(1 - \rho(t))(1 - \theta)^2 \left[\left(\frac{K}{2} \right) \cdot RBC_{\text{tot}_2}^2 - K \cdot RBC_{\text{tot}_2}^2 \right] \\ &= -k_{\text{agg}}\rho(t)(1 - \rho(t))(1 - \theta)^2 \left(\frac{K}{2} \right) \cdot RBC_{\text{tot}_2}^2. \end{aligned}$$

448 Integrating once gives:

$$B_N(t) = \frac{RBC_{\text{tot}_2}}{1 + \left(\frac{k_{\text{agg}}}{2} \right) \rho(t)(1 - \rho(t))(1 - \theta)^2 RBC_{\text{tot}_2} t}. \quad (4)$$

449 Here, we set $K = 1$ such that the effect of K is lumped into k_{agg} because we estimated k_{agg}
 450 from data (see below).

451 *Assay step 3: determination of HI titer*

452 We define the degree of hemagglutination as:

$$h(t) = \left(1 - \frac{B_N(t)}{RBC_{\text{tot}_2}} \right) \cdot 100, \quad (5)$$

453 such that it takes values between 0% and 100%. If there is no hemagglutination, the concentra-
 454 tion of agglutinated particles is the same as the initial concentration of RBCs ($B_N(t) = RBC_{\text{tot}_2}$)
 455 and the degree of hemagglutination is 0%. If all RBCs are agglutinated, there is only one agglu-
 456 tinating particle in the system and $B_N(t) = 1/N_A \cdot 10^9$ nM, where N_A is Avogadro's number.
 457 Since $N_A \approx 6 \cdot 10^{23}$, $B_N \approx 10^{-15} \approx 0$ nM such that $h(t) = 100\%$.

458 **Model implementation**

459 To obtain the degree of hemagglutination $h(t)$ in Equation 5, we compute θ from Equation 1,
 460 $\rho(t)$ for any time point t in assay step 2 from Equations 2 and 3, and the corresponding $B_N(t)$
 461 from Equation 4.

462 In addition, the total concentration of antibodies is given by

$$A_{\text{tot}_1} = 0.5 \cdot d_p \cdot d^j \cdot A_0,$$

463 where A_0 is the initial serum antibody concentration, d_p is the serum predilution factor, d the
 464 serial dilution factor and j the considered dilution step. The total concentrations of virus are

$$V_{\text{tot}_1} = 0.5 \cdot V_0 \text{ and } V_{\text{tot}_2} = 0.5 \cdot V_{\text{tot}_1},$$

465 because each assay step involves adding equal volumes of solution; V_0 is the initial virus con-
 466 centration. Analogously,

$$RBC_{\text{tot}_2} = 0.5 \cdot RBC_0,$$

467 where RBC_0 is the initial concentration of RBCs.

468 The model is implemented in the R package `himodel` (<https://gitlab.com/csb.ethz/himodel>).

469 **Model parameters and initial conditions**

470 All model parameters and initial conditions could be either extracted or derived from literature
 471 (summarized in **Table 1**), except for the agglutination rate of RBCs (k_{agg}), which we estimated
 472 from data as described below.

473 *RBC concentration (RBC_0)*

474 Following the WHO protocol (WHO, 2002), a 0.75% (v/v) suspension of chicken RBCs is
 475 used to measure HI titers against H1N1pdm09. This corresponds approximately to $1.875 \cdot 10^6$
 476 cells/mL (Tyrrell and Valentine, 1957). Given that 1 mol corresponds to $6.022 \cdot 10^{23}$ cells,
 477 the molar concentration is approximately $RBC_0 = 3.1 \cdot 10^{-5}$ nM. To determine the effect of
 478 pipetting errors, we set the RBC concentration range in the sensitivity analysis to 0.375% –
 479 1.5% (v/v) suspension, which corresponds to approximately $1.6 \cdot 10^{-5} - 6.3 \cdot 10^{-5}$ nM.

480 *Number of sialic acid-linked receptors on RBC (b)*

481 Influenza hemagglutinin binds to SA-linked surface receptors of RBCs. Human H1 influenza
 482 viruses bind preferentially to $\alpha 2 \rightarrow 6$ linked SA (Rogers and D’Souza, 1989), which occurs
 483 on the surface of chicken RBCs mainly in N-linked glycans (Aich et al., 2011; Aoki, 2017).
 484 Chicken RBCs contain a mixture of $\alpha 2 \rightarrow 3$ and $\alpha 2 \rightarrow 6$ -linked glycans in a ratio of approx-
 485 imately 60:40 – 50:50 (Aich et al., 2011). The total number of N-glycan on RBCs has been
 486 estimated to be $1 \cdot 10^6$ (Aoki, 2017). Thus, we assume that the average number of receptors that
 487 can interact with hemagglutinin is $0.45 \cdot 10^6$. Chicken RBCs also have SA-linked O-glycans such
 488 as glycophorins (Duk et al., 2000) on their surface, but most of them contain $\alpha 2 \rightarrow 3$ -linked
 489 SA. Therefore, we neglect them.

490 *Steric virus factor (b^*): number of sialic acid-linked receptors covered by bound virions*

491 Influenza virions are approximately 60-times smaller than RBCs (Harris et al., 2006). To model
 492 the binding of virions to RBCs, we need to take into account that bound virions cover multiple
 493 SA-linked receptors. We estimated the average number of covered $\alpha 2 \rightarrow 6$ SA-linked receptors,
 494 b^* , from simple geometry. We assume that SA-linked receptors are uniformly distributed on
 495 RBCs. Their estimated surface area ranges from 140 – 160 μm^2 and we assume an average
 496 surface area of $A_{\text{RBC}} = 150 \cdot 10^6 \text{ nm}^2$ (Ballas, 1987; Movassaghian and Torchilin, 2015). The
 497 virus-covered area is determined by the virus’ diameter. Most influenza virions are spherical
 498 with a diameter ranging from 84 – 170 nm and mean diameter $d = 120 \text{ nm}$ (Harris et al., 2006).
 499 We estimate the shaded area from the circle area, which yields:

$$b^* = \frac{\pi(d/2)^2}{A_{\text{RBC}}} \cdot b \approx 34. \quad (6)$$

500 In the sensitivity analysis, we sample b^* assuming $d \sim \text{Unif}(84, 170)$, $A_{\text{RBC}} \sim \text{Unif}(130 \cdot$
 501 $10^6, 170 \cdot 10^6)$, and $b \sim \text{Unif}(0.4 \cdot 10^6, 0.5 \cdot 10^6)$, where d has unit nm, A_{RBC} has unit nm^2 and
 502 b is unitless.

503 *Virus concentrations (V_0)*

504 To ensure the reproducibility of the HI assay, the same amount of virus particles must be used
 505 in each experiment. Therefore, virus concentration is measured in HA units, an operational unit
 506 that is determined in the so called HA titration assay, where virus is titrated against a constant
 507 amount of RBCs (same amount as used in the HI assay, i.e. 50 μ L of 0.75% (v/v) RBC suspen-
 508 sion are added to 50 μ L serum-virus dilution). The amount of virus that agglutinates an equal
 509 volume of standardized RBC suspension is defined as 1 HA unit (WHO, 2002). Electron mi-
 510 croscopy data show that partial hemagglutination occurs at 1:1 binding (on average, one virus
 511 particle binds to one RBC) (Tyrrell and Valentine, 1957). We assume that full hemagglutination
 512 requires at least 2:1 binding. We used the rate equation for virus-RBC binding (Equation 2)
 513 to determine the virus concentration that leads to 2:1 binding with $0.5 \cdot 3.1 \cdot 10^{-5}$ nM RBC
 514 (**Supplementary Figure S1a**): $3.2 \cdot 10^{-5}$ nM. Assuming that this virus concentration corre-
 515 sponds to 1 HA unit in our model simulations, 4 HA units are approximately $V_0 = 1.3 \cdot 10^{-3}$
 516 nM. In the sensitivity analysis, we varied V_0 in the range of 3 – 7 HA units.

517 *Agglutination rate (k_{agg})*

518 We inferred the agglutination rate of RBCs from HI titer and serum IgG concentration of the
 519 reference serum using the inference procedure described in the next section. We used a broad
 520 uniform prior for $k_{\text{agg}} \sim \text{Uniform}(10^5, 10^9)$, set the coagulation kernel K to 1 and fixed all re-
 521 maining parameters to the values in **Table 1**. The k_{agg} posterior distribution was approximately
 522 log-normal (centered at around $2 \cdot 10^6 \text{ s}^{-1}$ with 95% credibility interval of approximately $0.4 \cdot 10^6$
 523 – $13 \cdot 10^6 \text{ s}^{-1}$) with slightly heavier tail towards larger k_{agg} values since hemagglutination reaches
 524 saturation at approximately 30 min (**Supplementary Figure S1b**). Data at earlier time points
 525 would be needed to infer k_{agg} with higher precision. We set $k_{\text{agg}} = 2 \cdot 10^6 \text{ s}^{-1}$; the precision
 526 suffices as we are interested in hemagglutination at ≥ 30 min.

527 **Inference of neutralizing antibody avidities**

528 Given a measured IgG antibody concentration A_i of serum sample i (with estimated log mean
 529 $\mu_{A,i}$ and log standard deviation $\sigma_{A,i}$) and the corresponding HI titer determined in an HI assay
 530 with $j = 1, \dots, J$ dilution steps, serum predilution factor d_p , and serial dilution factor d , the
 531 generative model to infer the posterior distributions for $K_{D,i}^{\text{app}}$ is defined as follows:

$$\begin{aligned}
 K_{D,i}^{\text{app}} &\sim \text{Lognormal}(\mu_K, \sigma_K^2) \\
 A_i &\sim \text{Lognormal}(\mu_{A,i}, \sigma_{A,i}^2) \\
 A_{0,ij} &= A_i \cdot d_p \cdot d^j \\
 \theta_{ij} &= f_\theta(A_{0,ij}, K_{D,i}^{\text{app}}) \\
 \rho_{ij} &= f_\rho(\theta_{ij}) \\
 h_{ij} &= f_h(\rho_{ij}, \theta_{ij}) \\
 p_{ij} &= \text{logit}^{-1}(\alpha(h_{ij} - h_0)) \\
 y_{ij} &\sim \text{Bernoulli}(p_{ij}).
 \end{aligned}$$

532 Here, $A_{0,ij}$ is the final concentration of diluted serum IgG at dilution step j . It gives rise to
 533 sample- and dilution-specific θ_{ij} , ρ_{ij} , and h_{ij} as defined by Equations 1, 3 and 5 (here abbrevi-
 534 ated for convenience with f_θ , f_ρ and f_h and with time dependencies dropped).

535 To determine the HI titer, each serum dilution j is inspected for hemagglutination inhibition,
 536 and the reciprocal value of the minimal dilution that shows full inhibition is the HI titer. We
 537 treat the binary decision at each dilution step (inhibition/no inhibition) as a Bernoulli process
 538 with inhibition probability p_{ij} , a shorthand notation for $P(y_{ij} = 1 | h_{ij})$. The indicator variable
 539 y_{ij} takes the value 0 if the hemagglutination degree h_{ij} is above a certain threshold h_0 (no
 540 inhibition) and 1 otherwise (inhibition):

$$y_{ij} = \begin{cases} 0, & \text{if } h_{ij} > h_0 \text{ (no inhibition),} \\ 1, & \text{if } h_{ij} \leq h_0 \text{ (inhibition).} \end{cases} \quad (7)$$

541 This binary decision is modelled by a logistic function with steepness parameter α and inflection
 542 point h_0 . The conditional likelihood for $\mathbf{y}_i^T = (y_{i1}, y_{i2}, \dots, y_{iJ})$ over all J dilutions is then given
 543 by a product of Bernoulli likelihoods:

$$P(\mathbf{y}_i | K_{D,i}^{\text{app}}, A_i) = \prod_{j=1}^J p_{ij}^{y_{ij}} \cdot (1 - p_{ij})^{(1-y_{ij})} \quad (8)$$

and the full posterior is:

$$P(K_{D,i}^{\text{app}}, A_i | \mathbf{y}_i) = \frac{P(K_{D,i}^{\text{app}}) P(A_i) P(\mathbf{y}_i | K_{D,i}^{\text{app}}, A_i)}{P(\mathbf{y}_i)}. \quad (9)$$

We sampled posterior distributions using the Metropolis-Hastings algorithm (Brooks et al., 2011) with 6000 samples, burn-in size of 1000 samples, and 5 chains. We used a broad log-normal prior for $K_{D,i}^{\text{app}}$ centered at 1 nM with log mean $\mu_k = 0$ and log standard deviation $\sigma_K = 4$. To define the value of h_0 , we investigated the relationship between HA units and hemagglutination degree in our HA titration simulations. The model predicted that the hemagglutination degree is $> 75\%$ for ≥ 1 HA unit (**Supplementary Figure S1c**), which by definition corresponds to full hemagglutination. Thus, assuming symmetry, we consider $h_0 = 25\%$ a reasonable estimate, also assuming that differences below 25% cannot be distinguished by eye. However, a different value for h_0 does not affect the interpretation of our results: it would only shift the maximum a posteriori (MAP) estimates of all samples either towards lower avidities (for larger h_0) or higher avidities (for smaller h_0). Steepness parameter α does not affect the MAP estimate, but only the width of the posterior distribution. Here, we set $\alpha = 15$ and then investigated the relationship between posterior distribution and resulting HI titer by sampling. We sampled 500 times from the joint posterior distribution of $K_{D,i}^{\text{app}}$ and A_i for all patient sera i and predicted the resulting HI titer to investigate the uncertainty in $K_{D,i}^{\text{app}}$ due to discretization of HI titer measurements. On average, approximately 55% of samples resulted in the observed HI titer, whereas approximately 95% of samples also included HI titers one dilution step higher or lower than the actually observed HI titer.

Sensitivity analysis

Sobol sensitivity analysis attributes variance in model output to individual model input factors using variance decomposition (Saltelli et al., 2004). Given k model inputs, the total variance $V(y)$ in model output can be decomposed as:

$$V(y) = \sum_i V_i + \sum_i \sum_{j>i} V_{ij} + \dots + V_{12\dots k}, \quad (10)$$

where $V_i = V(E(Y|x_i))$ is the variance with respect to the distribution of input factor x_i . The second-order interaction term $V_{ij} = V(E(Y|x_i, x_j)) - V_i - V_j$ captures the part of the effect of x_i and x_j that is not described by the first order terms V_i , V_j and so on. The relative contribution of each term to the unconditional variance $V(y)$ serves as a measure of sensitivity. For instance, V_i will be large, if x_i is influential. The first order Sobol sensitivity index is defined as

$$S_i = \frac{V_i}{V(y)}. \quad (11)$$

To obtain the total contribution of x_i , that is the sum of all terms in the variance decomposition that include x_i , we compute the total contribution to variance $V(y)$ due to all factors but x_i , denoted by $\mathbf{x}_{-i}$. The total Sobol sensitivity index for x_i is then given by

$$S_i^T = \frac{V(y) - V(E(y|\mathbf{x}_{-i}))}{V(y)}. \quad (12)$$

We used Monte Carlo estimation to estimate Sobol indices (Jansen, 1999; Saltelli et al., 2010) implemented in the R package *sensitivity* (Iooss et al., 2019) with $n = 10000$ random samples of model input vector $\mathbf{x}^T = (x_1, x_2, \dots, x_k)$ and 10 bootstrap replicates to estimate confidence intervals. Input variables were assumed to be independent of each other. We considered $k = 12$ inputs sampled within a biologically reasonable range (**Table 1**).

Ethics statement

The study was conducted in accordance with the Declaration of Helsinki and approved by the Ethic committee northwest and central Switzerland (EKNZ ID 2014-141). All patients signed informed consent.

Patient sera

Adult patients that received allogeneic hematopoietic stem cell transplantation (HSCT) at least one year before were recruited in a multicenter cohort study at three hematological centers in Switzerland (at the University Hospital Basel and the Cantonal Hospitals in Aarau and Lucerne) between October 2014 and January 2015. Only patients without known vaccine intolerance such as egg protein allergy or vaccine-associated adverse events were eligible for participation. In total, 57 patients were recruited; we included 45 of them in the present study based on the availability of serum samples. Following the standard of care for HSCT patients, each patient received two doses of non-adjuvanted trivalent influenza vaccine (TIV), where the second dose was given 30 days after the first. Serum samples were collected prior to first vaccination (d0) and after vaccination (d7, d30, d60, d180) and stored in aliquots at -80°C . Almost all patients were in complete remission (42/45, 93%), and no patient showed progression. In the present study, 16 patients (36%) were within the first two years after HSC transplantation. 20 patients (44%) showed seroprotective titers against H1N1pdm09 before vaccination. As classified by the treating physician, 26 (60%) were immunosuppressed, of which 7 (16%) were classified with severe immunosuppression (grade 3). According to NIH consensus criteria (Filipovich et al., 2005), 30 patients suffered from chronic GVHD, of which 11 (24%) were classified with severe chronic GVHD (grade 3). An overview of patient's baseline characteristics is given in **Table 2**.

Vaccine composition

Patients received two doses of the non-adjuvanted 2014/2015 trivalent influenza vaccine (Agrimipal, Novartis, Switzerland), comprising inactivated, subunit influenza virus with $15\ \mu\text{g}$ HA antigen of each vaccine strain: A/California/7/2009 (H1N1pdm09), A/Texas/50/2012 (H3N2) and B/Massachusetts/2/2012 (Yamagata lineage).

Table 2. Characteristics of allogeneic hematopoietic stem cell transplant patients (all patients and subset of patients with experimentally determined avidities for validation of inferred avidities).

		All	Validation subset
Total		45	12
Age	Median, IQR (years)	58, 44-64	45, 43-67
	≥ 65 years	11 (25%)	4 (33%)
Sex	Male	23 (51%)	4 (33%)
	Female	22 (49%)	8 (67%)
Underlying disease	Acute myeloid leukemia (AML)	17 (38%)	6 (50%)
	Acute lymphoblastic leukemia (ALL)	8 (18%)	2 (17%)
	Chronic myeloid leukemia (CML)	5 (11%)	1 (8%)
	Chronic lymphocytic leukemia (CLL)	5 (11%)	1 (8%)
	Multiple myeloma (MM)	5 (11%)	1 (8%)
	Plasma cell leukemia (PCL)	1 (2%)	0
	Myeloproliferative neoplasms (MPN)	1 (2%)	1 (8%)
	Myelodysplastic syndromes (MDS)	2 (4%)	0
	Non-Hodgkin lymphoma (NHL)	1 (2%)	0
Time after transplantation	median, IQR (years)	4, 2-8	6, 3-8
	1-2 years	16 (36%)	2 (17%)
	3-5 years	13 (29%)	3 (25%)
	> 5 years	16 (36%)	7 (58%)
Transplant source	Peripheral blood	40 (89%)	11 (92%)
	Bone marrow	5 (11%)	1 (8%)
Donor source	Matched related donor	16 (36%)	5 (42%)
	Matched unrelated donor	21 (47%)	5 (42%)
Disease status ^a	Complete remission	42 (93%)	12 (100%)
	Stable	1 (2%)	0
	Recurrence	2 (4%)	0
	Progressive	0	0
Immunosuppression ^a	None	18 (40%)	2 (17%)
	Mild (grade 1)	6 (13%)	2 (17%)
	Moderate (grade 2)	14 (31%)	6 (50%)
	Severe (grade 3)	7 (16%)	2 (17%)
Immunosuppressive treatment ^a	Prednisone	13 (29%)	5 (42%)
	Tacrolimus	14 (31%)	7 (58%)
	Mycophenolate ^b	9 (20%)	3 (25%)
	Cyclosporine A ^c	4 (9%)	0
	Rituximab ^d	3 (7%)	0
Chronic GVHD	None	15 (33%)	0
	Mild (grade 1)	9 (20%)	4 (33%)
	Moderate (grade 2)	10 (22%)	6 (50%)
	Severe (grade 3)	11 (24%)	2 (17%)

Abbreviations: IQR: interquartile range; GVHD: graft-versus-host disease.

^aBefore vaccination, ^bCellCept® or Myfortic®, ^cSandimmun®, ^dMabThera® within the previous six months.

606 **HI assay**

607 HI assays were performed according to the WHO manual (WHO, 2002). Sera were pre-treated
608 with receptor destroying enzyme (RDE); Sigma-Aldrich, C8772) and two-fold serially diluted,
609 covering dilutions from 1:8 to 1:2048. A 0.75% (v/v) suspension of chicken RBCs (Cedarlane,
610 CLC8800) and 4 HA units of influenza H1N1pdm09 virus (NYMC-X181) were used to perform
611 the assay. The reported HI titer is the dilution factor of the highest serum dilution that showed
612 full hemagglutination inhibition. The protocol has been published in detail (Kaufmann et al.,
613 2017).

614 **ELISA for influenza-specific IgG detection**

615 ELISA 96-well plates (Thermo Scientific, 442404) were coated with 0.5 µg/mL whole virus
616 H1N1pdm09 (NYMC-X181, 45 µg HA/mL) at 4°C overnight. Plates were blocked with 5%
617 bovine serum albumin (BSA) in PBS for 1h at room temperature (RT). Patient serum samples
618 were 1:4000 diluted in 0.5% BSA in PBS. Reference serum was 1:1000 diluted (top dilution
619 of calibration curve) and then six times four-fold serially diluted, yielding a calibration curve
620 with seven measurements. After blocking and washing with 0.05% TWEEN 20 in PBS, 100
621 µL/well of diluted serum samples were added and incubated for 2h at RT. Unbound serum an-
622 tibodies were removed by washing the plates four times, and bound serum IgG was detected
623 by 70µL/well of 1:3000 diluted rabbit anti-human IgG antibody linked to horseradish peroxi-
624 dase (Agilent, P021402-2) incubated for 2h at RT. After washing, plates were developed with
625 100 µL/well TMB substrate solution (BD, 555214) for 15 min and stopped with 50 µL/well
626 2N H₂SO₄. Absorbance was measured at 450 and 620 nm. Measurements were background-
627 and blank-corrected. To obtain a calibration curve, reference measurements were fitted using a
628 four-parameter logistic equation (log concentration vs log absorbance). All measurements were
629 performed in duplicates.

630 **Urea elution assay to measure IgG avidities**

631 The ELISA assay described above was adapted to measure serum IgG avidities against influenza
632 H1N1pdm09. Each serum was accordingly diluted to obtain a final concentration within the lin-
633 ear range of the calibration curve. After incubation with serum and washing as described above,
634 each well was incubated for an additional 3h at RT with either 100 µL/well 4M urea (treated)
635 or 100 µL/well PBS (untreated). The concentration of bound IgG was determined using a cal-
636 ibration curve, as described above. The fraction of IgG remaining bound after urea treatment
637 compared to the untreated wells is reported as the avidity index. Avidities were determined in
638 two experiments, each performed in duplicates.

639 Reference serum

640 The concentration of H1N1pdm09-specific IgG antibodies was determined in ELISA experi-
 641 ments relative to a reference serum collected from a healthy volunteer on day 7 after vaccination
 642 with 2014/2015 TIV (Agripal, Novartis, Switzerland), showing an HI titer of 512. Since the
 643 absolute reference concentration could only be determined by mass spectrometry, which was not
 644 feasible in this study, we estimated the concentration based on reported H1N1pdm09-specific
 645 IgG concentrations in vaccinated healthy adults with similar HI titers (Eidem et al., 2015). We
 646 set the reference concentration to 100 $\mu\text{g/mL}$ (670 nM), yielding an estimated avidity for the
 647 reference serum of 0.4 - 0.8 nM, consistent with observed affinities for post-vaccination serum
 648 IgG for H1N1pdm09 in healthy adults (Lee et al., 2016).

649 Identification of patients with increase in avidity and increase in non-neutralizing IgG

650 For each inferred K_D^{app} value, we identified the uncertainty interval due to ELISA measurement
 651 error and dichotomization in HI titers by sampling from the joint posterior distribution (see
 652 above) and considered non-overlapping intervals as a significant change in K_D^{app} . To detect
 653 patients that produced non-neutralizing IgG after vaccination, we identified patients that showed
 654 no increase in HI titer while showing an increase in serum IgG that resulted in a significant
 655 decrease in avidity (**Supplementary Figure S4a**).

656 Statistical analysis

657 Serum IgG and inferred K_D^{app} values were available for 43 patients at five time points ($t =$
 658 0, 7, 30, 60, 180 days) with 197 observations in total. To estimate the effects of a patient's im-
 659 mune state on serum IgG and avidity ($1/K_D^{\text{app}}$), we used a linear mixed model with patient-
 660 specific random intercepts that takes the following general form:

$$\begin{aligned} y_{ij} &= \beta_0 + x_{ij}^T \beta_1 + \gamma_i + \epsilon_{ij}, \\ \gamma_i &\sim \mathcal{N}(0, \sigma_\gamma^2), \\ \epsilon_{ij} &\sim \mathcal{N}(0, \sigma_\epsilon^2), \end{aligned}$$

661 where y_{ij} is the log2-transformed IgG concentration or $1/K_D^{\text{app}}$ value, respectively, of patient
 662 i at time point j , x_{ij} is a p -dimensional vector of p covariates, β_0 is an intercept term, β_1 is
 663 a vector of fixed effects, γ_i the random patient-specific intercept, and ϵ_{ij} models the within-
 664 patient measurement error. We modeled the observed rise and fall of serum IgG and $1/K_D^{\text{app}}$
 665 value after vaccination using a second-degree polynomial. To distinguish time trends in avidity
 666 between neutralizing and non-neutralizing IgG responders, we added a dummy variable for

neutralizing response when analyzing response in avidity. Time post HSCT ≤ 2 years, cGVHD grade, and immunosuppression grade were added as fixed effects on intercept to investigate effects on baseline, and on slope to investigate effects on response. Time post HSCT ≤ 2 years was encoded as a binary variable (1 for ≤ 2 years, 0 for > 2 years). Both cGVHD and immunosuppression grade were encoded as numerical variables with values 0, 1, 2, 3, such that grade 0 is the reference level, and there is a linear increase in effect with increasing grade. To control for potential confounders, we corrected for sex and age. For model selection, the full model with fixed effects on slope and intercept was fitted using maximum likelihood estimation implemented in the `lmer4` package (Bates et al., 2015) and type II ANOVA by Satterthwaite's approximation provided by the `lmerTest` package (Kuznetsova et al., 2017).

We detected no significant effects on response for serum IgG and avidity. Therefore, we removed fixed effects on slope and refitted the final models using restricted maximum likelihood estimation to obtain unbiased estimates (Bates et al., 2015). Residuals indicated that the normality assumption was satisfied (**Supplementary Figure S4b**). Confidence intervals were computed via the Wald method provided by `lme4`. To compare the results with HI titers, we estimated the effect of time post HSCT ≤ 2 years, cGVHD grade, and immunosuppression on HI titers controlling for age, sex, and time after vaccination using a generalized linear regression model for sequential, ordered data (Tutz, 1991). The model was fitted using maximum likelihood estimation implemented in `VGAM` (Yee et al., 2010).

Data and software availability

The model is available in the R package `himodel` (<https://gitlab.com/csb.ethz/himodel>). Source files necessary to reproduce the results of this work are available on GitLab (<https://gitlab.com/csb.ethz/himodel-manuscript>).

Conflict of interests

None.

Author contributions

JL, JS, and AE designed the study. JL and JS developed the model. JL and MS designed and performed experiments. JL analyzed data, implemented the model, and performed simulations. JH and YH recruited patients, collected patient samples, and patient information. YH, JH and AE consulted on medical questions. JS and AE supervised the project. JL and JS wrote the first draft of the manuscript, and all authors commented on the final version.

698 Acknowledgments

699 We thank our clinical collaborators Nathan Cantoni (Cantonal Hospital Aarau), and Sabine
700 Ruosch (Cantonal Hospital Lucerne) for providing patient sera and supporting the cohort study.
701 We thank Dominik Vogt and Lukas Kaufmann for technical support with patient samples and
702 Fabian Rudolf for advice on the experimental design of avidity measurements.

703 References

- 704 U. Aich, N. Beckley, Z. Shriver, R. Raman, K. Viswanathan, S. Hobbie, and R. Sasisekharan.
705 Glycomics-based analysis of chicken red blood cells provides insight into the selectivity of
706 the viral agglutination assay. *The FEBS journal*, 278(10):1699–1712, 2011.
- 707 M. O. Altman, J. R. Bennink, J. W. Yewdell, and B. R. Herrin. Lamprey VLRB response to
708 influenza virus supports universal rules of immunogenicity and antigenicity. *Elife*, 4:e07467,
709 2015.
- 710 D. Angeletti, J. S. Gibbs, M. Angel, I. Kosik, H. D. Hickman, G. M. Frank, S. R. Das, A. K.
711 Wheatley, M. Prabhakaran, D. J. Leggat, et al. Defining B cell immunodominance to viruses.
712 *Nature immunology*, 18(4):456, 2017.
- 713 T. Aoki. A comprehensive review of our current understanding of red blood cell (RBC) glyco-
714 proteins. *Membranes*, 7(4):56, 2017.
- 715 P. Arevalo, H. Q. McLean, E. A. Belongia, and S. Cobey. Earliest infections predict the age
716 distribution of seasonal influenza a cases. *Elife*, 9:e50060, 2020.
- 717 S. K. Ballas. Erythrocyte concentration and volume are inversely related. *Clinica chimica acta;*
718 *international journal of clinical chemistry*, 164(2):243–244, 1987.
- 719 D. Bates, M. Mächler, B. Bolker, and S. Walker. Fitting linear mixed-effects models using lme4.
720 *Journal of Statistical Software*, 67(1):1–48, 2015. doi: 10.18637/jss.v067.i01.
- 721 A. Benoit, J. Beran, J.-M. Devaster, M. Esen, O. Launay, G. Leroux-Roels, J. E. McElhaney,
722 L. Oostvogels, G. A. van Essen, M. Gaglani, et al. Hemagglutination inhibition antibody
723 titers as a correlate of protection against seasonal A/H3N2 influenza disease. In *Open forum*
724 *infectious diseases*, volume 2, page ofv067. Oxford University Press, 2015.
- 725 C. Berek, A. Berger, and M. Apel. Maturation of the immune response in germinal centers.
726 *Cell*, 67(6):1121–1129, 1991.
- 727 S. Brooks, A. Gelman, G. Jones, and X.-L. Meng. *Handbook of markov chain monte carlo*.
728 CRC press, 2011.
- 729 G. W. Brunette, P. E. Kozarsky, and N. J. Cohen. *CDC health information for international*
730 *travel 2016: the yellow book*. Oxford University Press, USA, 2015.

731 N. S. De Silva and U. Klein. Dynamics of B cells in germinal centres. *Nature reviews immunol-*
732 *ogy*, 15(3):137–148, 2015.

733 E. B. Dolgosheina, A. Y. Karulin, and A. V. Bobylev. A kinetic model of the agglutination
734 process. *Mathematical biosciences*, 109(1):1–10, 1992.

735 M. Duk, H. Krotkiewski, T. V. Stasyk, M. Lutsik-Kordovsky, D. Syper, and E. Lisowska. Iso-
736 lation and characterization of glycophorin from nucleated (chicken) erythrocytes. *Archives*
737 *of biochemistry and biophysics*, 375(1):111–118, 2000.

738 M. Edwards and N. Dimmock. Two influenza A virus-specific Fabs neutralize by inhibiting
739 virus attachment to target cells, while neutralization by their IgGs is complex and occurs
740 simultaneously through fusion inhibition and attachment inhibition. *Virology*, 278(2):423–
741 435, 2000.

742 S. Eidem, S. M. Tete, Å. Jul-Larsen, K. Hoschler, E. Montomoli, K. A. Brokstad, and R. J. Cox.
743 Persistence and avidity maturation of antibodies to A (H1N1) pdm09 in healthcare workers
744 following repeated annual vaccinations. *Vaccine*, 33(33):4146–4154, 2015.

745 A. H. Ellebedy. Immunizing the immune: can we overcome influenza’s most formidable chal-
746 lenge? *Vaccines*, 6(4):68, 2018.

747 D. Engelhard, Z. Zakay-Rones, M. Y. Shapira, I. Resnick, D. Averbuch, S. Grisariu, L. Dray,
748 E. Djian, N. Strauss-Liviatan, I. Grotto, et al. The humoral immune response of hematopoietic
749 stem cell transplantation recipients to AS03-adjuvanted A/California/7/2009 (H1N1) v-like
750 virus vaccine during the 2009 pandemic. *Vaccine*, 29(9):1777–1782, 2011.

751 A. H. Filipovich, D. Weisdorf, S. Pavletic, G. Socie, J. R. Wingard, S. J. Lee, P. Martin, J. Chien,
752 D. Przepiorka, D. Couriel, et al. National Institutes of Health consensus development project
753 on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging
754 working group report. *Biology of blood and marrow transplantation*, 11(12):945–956, 2005.

755 G. M. Frank, D. Angeletti, W. L. Ince, J. S. Gibbs, S. Khurana, A. K. Wheatley, E. E. Max, A. B.
756 McDermott, H. Golding, J. Stevens, et al. A simple flow-cytometric method measuring b cell
757 surface immunoglobulin avidity enables characterization of affinity maturation to influenza
758 A virus. *MBio*, 6(4):e01156–15, 2015.

759 W. Gerhard, J. Yewdell, M. E. Frankel, and R. Webster. Antigenic structure of influenza virus
760 haemagglutinin defined by hybridoma antibodies. *Nature*, 290(5808):713, 1981.

761 A. Gonzalez-Quintela, R. Alende, F. Gude, J. Campos, J. Rey, L. Meijide, C. Fernandez-Merino,
762 and C. Vidal. Serum levels of immunoglobulins (IgG, IgA, IgM) in a general adult population
763 and their relationship with alcohol consumption, smoking and common metabolic abnormal-
764 ities. *Clinical & Experimental Immunology*, 151(1):42–50, 2008.

- 765 H. T. Greinix, D. Pohlreich, M. Kouba, U. Körmöczi, I. Lohmann, K. Feldmann, C. Zielinski,
766 and W. F. Pickl. Elevated numbers of immature/transitional CD21- B lymphocytes and de-
767 ficiency of memory CD27+ B cells identify patients with active chronic graft-versus-host
768 disease. *Biology of Blood and Marrow Transplantation*, 14(2):208–219, 2008.
- 769 S. F. d. S. Groth. The neutralization of viruses. In *Advances in Virus Research*, volume 9, pages
770 1–125. Elsevier, 1963.
- 771 S. Gueller, R. Allwinn, S. Mousset, H. Martin, I. Wieters, E. Herrmann, H. Serve, M. Bickel,
772 and G. Bug. Enhanced immune response after a second dose of an AS03-adjuvanted H1N1
773 influenza A vaccine in patients after hematopoietic stem cell transplantation. *Biology of*
774 *Blood and Marrow Transplantation*, 17(10):1546–1550, 2011.
- 775 A. Harris, G. Cardone, D. C. Winkler, J. B. Heymann, M. Brecher, J. M. White, and A. C.
776 Steven. Influenza virus pleiomorphy characterized by cryoelectron tomography. *Proceedings*
777 *of the National Academy of Sciences*, 103(50):19123–19127, 2006.
- 778 A. K. Harris, J. R. Meyerson, Y. Matsuoka, O. Kuybeda, A. Moran, D. Bliss, S. R. Das, J. W.
779 Yewdell, G. Sapiro, K. Subbarao, et al. Structure and accessibility of HA trimers on intact
780 2009 H1N1 pandemic influenza virus to stem region-specific neutralizing antibodies. *Pro-*
781 *ceedings of the National Academy of Sciences*, 110(12):4592–4597, 2013.
- 782 I. Hilgendorf, M. Freund, W. Jilg, H. Einsele, J. Gea-Banacloche, H. Greinix, J. Halter, A. Law-
783 itschka, D. Wolff, and R. Meisel. Vaccination of allogeneic haematopoietic stem cell trans-
784 plant recipients: report from the international consensus conference on clinical practice in
785 chronic GVHD. *Vaccine*, 29(16):2825–2833, 2011.
- 786 G. K. Hirst. The agglutination of red cells by allantoic fluid of chick embryos infected with
787 influenza virus. *Science*, 94(2427):22–23, 1941.
- 788 K. B. Hoehn, J. S. Turner, F. I. Miller, R. Jiang, O. G. Pybus, A. H. Ellebedy, and S. H. Kle-
789 instein. Human b cell lineages engaged by germinal centers following influenza vaccination
790 are measurably evolving. *bioRxiv*, 2021.
- 791 B. Iooss, A. Janon, G. Pujol, with contributions from Baptiste Broto, K. Boumhaout, S. D.
792 Veiga, T. Delage, J. Fruth, L. Gilquin, J. Guillaume, L. Le Gratiot, P. Lemaitre, A. Marrel,
793 A. Meynaoui, B. L. Nelson, F. Monari, R. Oomen, O. Rakovec, B. Ramos, O. Roustant,
794 E. Song, J. Staum, R. Sueur, T. Touati, and F. Weber. *sensitivity: Global Sensitivity Analysis*
795 *of Model Outputs*, 2019. URL <https://CRAN.R-project.org/package=sensitivity>.
796 R package version 1.16.2.
- 797 N. C. Issa, F. M. Marty, L. S. Gagne, S. Koo, K. A. Verrill, E. P. Alyea, C. S. Cutler, J. Koreth,
798 P. Armand, V. T. Ho, et al. Seroprotective titers against 2009 H1N1 influenza A virus after
799 vaccination in allogeneic hematopoietic stem cell transplantation recipients. *Biology of Blood*
800 *and Marrow Transplantation*, 17(3):434–438, 2011.

801 D. Jackson, B. Crabb, P. Pountourios, W. Tulip, and W. Laver. Three antibody molecules can
802 bind simultaneously to each monomer of the tetramer of influenza virus neuraminidase and
803 the trimer of influenza virus hemagglutinin. *Archives of virology*, 116(1-4):45–56, 1991.

804 C. A. Jacobson, L. Sun, H. T. Kim, S. M. McDonough, C. G. Reynolds, M. Schowalter, J. Ko-
805 reth, C. S. Cutler, V. T. Ho, E. P. Alyea, et al. Post-transplantation B cell activating factor
806 and B cell recovery before onset of chronic graft-versus-host disease. *Biology of Blood and*
807 *Marrow Transplantation*, 20(5):668–675, 2014.

808 M. J. Jansen. Analysis of variance designs for model output. *Computer Physics Communica-*
809 *tions*, 117(1-2):35–43, 1999.

810 L. Kaufmann, M. Syedbasha, D. Vogt, Y. Hollenstein, J. Hartmann, J. E. Linnik, and A. Egli.
811 An optimized hemagglutination inhibition (HI) assay to quantify influenza-specific antibody
812 titers. *JoVE (Journal of Visualized Experiments)*, (130):e55833, 2017.

813 S. Khurana, N. Verma, J. W. Yewdell, A. K. Hilbert, F. Castellino, M. Lattanzi, G. Del Giudice,
814 R. Rappuoli, and H. Golding. MF59 adjuvant enhances diversity and affinity of antibody-
815 mediated immune response to pandemic influenza vaccines. *Science translational medicine*,
816 3(85):85ra48–85ra48, 2011.

817 S. Khurana, D. Frasca, B. Blomberg, and H. Golding. AID activity in B cells strongly corre-
818 lates with polyclonal antibody affinity maturation in-vivo following pandemic 2009-H1N1
819 vaccination in humans. *PLoS pathogens*, 8(9), 2012.

820 S. Khurana, M. Hahn, E. M. Coyle, L. R. King, T.-L. Lin, J. Treanor, A. Sant, and H. Golding.
821 Repeat vaccination reduces antibody affinity maturation across different influenza vaccine
822 platforms in humans. *Nature communications*, 10(1):3338, 2019.

823 F. Krammer. Novel universal influenza virus vaccine approaches. *Current opinion in virology*,
824 17:95–103, 2016.

825 F. Krammer. The human antibody response to influenza a virus infection and vaccination.
826 *Nature Reviews Immunology*, 19(6):383–397, 2019.

827 K. M. Kunisaki and E. N. Janoff. Influenza in immunosuppressed populations: a review of
828 infection frequency, morbidity, mortality, and vaccine responses. *The Lancet infectious dis-*
829 *eases*, 9(8):493–504, 2009.

830 A. Kuznetsova, P. B. Brockhoff, and R. H. B. Christensen. lmerTest package: Tests in linear
831 mixed effects models. *Journal of Statistical Software*, 82(13):1–26, 2017. doi: 10.18637/jss.
832 v082.i13.

833 N. Kylilis, P. Riangrunroj, H.-E. Lai, V. Salema, L. A. Fernandez, G.-B. V. Stan, P. S.
834 Freemont, and K. M. Polizzi. Whole-cell biosensor with tunable limit of detection enables
835 low-cost agglutination assays for medical diagnostic applications. *ACS sensors*, 4(2):370–
836 378, 2019.

837 J. Lee, D. R. Boutz, V. Chromikova, M. G. Joyce, C. Vollmers, K. Leung, A. P. Horton, B. J.
838 DeKosky, C.-H. Lee, J. J. Lavinder, et al. Molecular-level analysis of the serum antibody
839 repertoire in young adults before and after seasonal influenza vaccination. *Nature medicine*,
840 22(12):1456, 2016.

841 Z.-N. Li, S.-C. Lin, P. J. Carney, J. Li, F. Liu, X. Lu, M. Liu, J. Stevens, M. Levine, J. M. Katz,
842 et al. IgM, IgG, and IgA antibody responses to influenza A (H1N1) pdm09 hemagglutinin
843 in infected persons during the first wave of the 2009 pandemic in the United States. *Clin.*
844 *Vaccine Immunol.*, 21(8):1054–1060, 2014.

845 M. Meyer-Hermann. Injection of antibodies against immunodominant epitopes tunes germinal
846 centers to generate broadly neutralizing antibodies. *Cell reports*, 29(5):1066–1073, 2019.

847 T. K. Ming, H. S. Goodman, and B. BROWN. Mathematical model for the process of aggrega-
848 tion in immune agglutination. *Nature*, 208(5005):84, 1965.

849 B. Mohty, M. Bel, M. Vukicevic, M. Nagy, E. Levrat, S. Meier, S. Grillet, C. Combescure,
850 L. Kaiser, Y. Chalandon, et al. Graft-versus-host disease is the major determinant of humoral
851 responses to the AS03-adjuvanted influenza A/09/H1N1 vaccine in allogeneic hematopoietic
852 stem cell transplant recipients. *haematologica*, 96(6):896–904, 2011.

853 S. Movassaghian and V. P. Torchilin. Long-circulating therapies for cancer treatment. In *Novel*
854 *Approaches and Strategies for Biologics, Vaccines and Cancer Therapies*, pages 433–462.
855 Elsevier, 2015.

856 J. Ogonek, M. Kralj Juric, S. Ghimire, P. R. Varanasi, E. Holler, H. Greinix, and E. Weissinger.
857 Immune reconstitution after allogeneic hematopoietic stem cell transplantation. *Frontiers in*
858 *immunology*, 7:507, 2016.

859 J. Olsson, J. Johansson, E. Honkala, B. Blomqvist, E. Kok, B. Weidung, H. Lövheim, and
860 F. Elgh. Urea dilution of serum for reproducible anti-HSV1 IgG avidity index. *BMC infec-*
861 *tious diseases*, 19(1):164, 2019.

862 W. Olszewska, O. E. Obeid, and M. W. Steward. Protection against measles virus-induced
863 encephalitis by anti-mimotope antibodies: the role of antibody affinity. *Virology*, 272(1):
864 98–105, 2000.

865 J. J. Otterstrom, B. Brandenburg, M. H. Koldijk, J. Juraszek, C. Tang, S. Mashaghi, T. Kwaks,
866 J. Goudsmit, R. Vogels, R. H. Friesen, et al. Relating influenza virus membrane fusion
867 kinetics to stoichiometry of neutralizing antibodies at the single-particle level. *Proceedings*
868 *of the National Academy of Sciences*, 111(48):E5143–E5148, 2014.

869 A. Palache, W. Beyer, G. Rimmelzwaan, A. Boon, A. Osterhaus, et al. Haemagglutination-
870 inhibiting antibody to influenza virus. *Developments in biologicals*, 115:63–73, 2003.

- 871 F. P. Polack, S. J. Hoffman, G. Crujeiras, and D. E. Griffin. A role for nonprotective complement-
872 fixing antibodies with low avidity for measles virus in atypical measles. *Nature medicine*, 9
873 (9):1209–1213, 2003.
- 874 P. Pournourios, L. E. Brown, D. O. White, and D. C. Jackson. The stoichiometry of binding
875 between monoclonal antibody molecules and the hemagglutinin of influenza virus. *Virology*,
876 179(2):768–776, 1990.
- 877 G. N. Rogers and B. L. D’Souza. Receptor binding properties of human and animal h1 influenza
878 virus isolates. *Virology*, 173(1):317–322, 1989.
- 879 D. Roll, J. Ammer, B. Holler, B. Salzberger, B. Schweiger, W. Jilg, R. Andreesen, M. Edinger,
880 D. Wolff, and E. Holler. Vaccination against pandemic H1N1 (2009) in patients after al-
881 logeneic hematopoietic stem cell transplantation: a retrospective analysis. *Infection*, 40(2):
882 153–161, 2012.
- 883 R. Ruigrok, P. Andree, R. H. Van Huysduynen, and J. Mellema. Characterization of three highly
884 purified influenza virus strains by electron microscopy. *Journal of general virology*, 65(4):
885 799–802, 1984.
- 886 A. Saltelli, S. Tarantola, F. Campolongo, and M. Ratto. *Sensitivity analysis in practice: a guide*
887 *to assessing scientific models*, volume 1. Wiley Online Library, 2004.
- 888 A. Saltelli, P. Annoni, I. Azzini, F. Campolongo, M. Ratto, and S. Tarantola. Variance based
889 sensitivity analysis of model output. design and estimator for the total sensitivity index. *Com-*
890 *puter Physics Communications*, 181(2):259–270, 2010.
- 891 S. Sarantopoulos, K. E. Stevenson, H. T. Kim, N. S. Bhuiya, C. S. Cutler, R. J. Soiffer, J. H.
892 Antin, and J. Ritz. High levels of B-cell activating factor in patients with active chronic
893 graft-versus-host disease. *Clinical Cancer Research*, 13(20):6107–6114, 2007.
- 894 S. Sarantopoulos, K. E. Stevenson, H. T. Kim, C. S. Cutler, N. S. Bhuiya, M. Schowalter, V. T.
895 Ho, E. P. Alyea, J. Koreth, B. R. Blazar, et al. Altered B-cell homeostasis and excess BAFF
896 in human chronic graft-versus-host disease. *Blood, The Journal of the American Society of*
897 *Hematology*, 113(16):3865–3874, 2009.
- 898 N. K. Sauter, M. D. Bednarski, B. A. Wurzburg, J. E. Hanson, G. M. Whitesides, J. J. Skehel, and
899 D. C. Wiley. Hemagglutinins from two influenza virus variants bind to sialic acid derivatives
900 with millimolar dissociation constants: a 500-MHz proton nuclear magnetic resonance study.
901 *Biochemistry*, 28(21):8388–8396, 1989.
- 902 N. K. Sauter, J. E. Hanson, G. D. Glick, J. H. Brown, R. L. Crowther, S. J. Park, J. J. Skehel,
903 and D. C. Wiley. Binding of influenza virus hemagglutinin to analogs of its cell-surface
904 receptor, sialic acid: analysis by proton nuclear magnetic resonance spectroscopy and X-ray
905 crystallography. *Biochemistry*, 31(40):9609–9621, 1992.

906 M. J. Shlomchik and F. Weisel. Germinal center selection and the development of memory B
907 and plasma cells. *Immunological reviews*, 247(1):52–63, 2012.

908 D. K. Takemoto, J. J. Skehel, and D. C. Wiley. A surface plasmon resonance assay for the
909 binding of influenza virus hemagglutinin to its sialic acid receptor. *Virology*, 217(2):452–
910 458, 1996.

911 H. Taylor, S. Armstrong, and N. Dimmock. Quantitative relationships between an influenza
912 virus and neutralizing antibody. *Virology*, 159(2):288–298, 1987.

913 C. M. Trombetta, E. J. Remarque, D. Mortier, and E. Montomoli. Comparison of hemagglu-
914 tination inhibition, single radial hemolysis, virus neutralization assays, and ELISA to detect
915 antibody levels against seasonal influenza viruses. *Influenza and Other Respiratory Viruses*,
916 12(6):675–686, 2018.

917 G. Tutz. Sequential models in categorical regression. *Computational Statistics & Data Analysis*,
918 11(3):275–295, 1991.

919 D. Tyrrell and R. Valentine. The assay of influenza virus particles by haemagglutination and
920 electron microscopy. *Microbiology*, 16(3):668–675, 1957.

921 P. A. Underwood. Problems and pitfalls with measurement of antibody affinity using solid phase
922 binding in the ELISA. *Journal of immunological methods*, 164(1):119–130, 1993.

923 M. Von Smoluchowski. Mathematical theory of the kinetics of the coagulation of colloidal
924 solutions. *Z. Phys. Chem*, 92(129):129–68, 1917.

925 E. G. Weinhold and J. R. Knowles. Design and evaluation of a tightly binding fluorescent
926 ligand for influenza A hemagglutinin. *Journal of the American Chemical Society*, 114(24):
927 9270–9275, 1992.

928 WHO. WHO manual on animal influenza diagnosis and surveillance. 2002.

929 J. A. Williams, L. Gui, N. Hom, A. Mileant, and K. K. Lee. Dissection of epitope-specific
930 mechanisms of neutralization of influenza virus by intact IgG and Fab fragments. *Journal of*
931 *Virology*, 92(6):e02006–17, 2018.

932 I. A. Wilson, J. J. Skehel, and D. Wiley. Structure of the haemagglutinin membrane glycoprotein
933 of influenza virus at 3 Å resolution. *Nature*, 289(5796):366–373, 1981.

934 T. W. Yee et al. The VGAM package for categorical data analysis. *Journal of Statistical Soft-*
935 *ware*, 32(10):1–34, 2010.

936 **Supplementary Figures**

Figure S1. Simulation results for the HA titration assay with influenza H1N1pdm09 and model sensitivity. (a) Binding kinetics of virus particles to red blood cells. We assume that full hemagglutination requires at least two bound virus particles per cell. (b) Hemagglutination kinetics. (c) For HA units ≥ 1 , the hemagglutination degree is $> 75\%$, which is by definition interpreted as full hemagglutination. Gray areas and error bars indicate the uncertainty due to uncertainty in model parameters. (d) Performing the HI assay with 4 HA units balances sensitivity and robustness. There is a clear distinction between inhibition and no inhibition. (e) At the same time, the assay detects with 4 HA units lower antibody concentrations than with ≥ 8 HA units.

Figure S2. Marginal posterior distributions of apparent dissociation constants in 43 patients (197 posteriors in total). Some posteriors show larger variance due to larger measurement error in ELISA-detected IgG concentrations.

Figure S3. HI titer, ELISA-detected anti-H1N1pmd09 serum IgG concentration, inferred apparent dissociation constant and experimentally determined avidity index in twelve patients. Avidity indices correspond to the fraction of H1N1pmd09-specific serum IgG remaining bound after 4M urea treatment. Data shows mean and standard deviation for serum IgG and avidity indices and the maximum a posteriori (MAP) estimates and uncertainty range due to discretized HI titer measurements and ELISA measurement error for inferred dissociation constants K_D^{app} . Most patients showed either little or no increase in avidity. In some patients, the measured avidity decreased and then returned back to baseline on d180, potentially because vaccine-induced short-term antibodies were more sensitive to urea treatment, resulting in antibody denaturation.

Figure S4. Vaccine response analysis in 43 patients (197 samples in total). (a) Fold change in inferred avidity and serum IgG after vaccination. Error bars indicate uncertainty in fold change due to uncertainty in inferred K_D^{app} -values. Shading indicates regions with qualitatively different responses to vaccination. (b) Tukey-Anscombe plot and histogram of the residuals of the regression models used to investigate differences in avidity and serum IgG.

Figure S5. Inferred avidity, serum IgG concentration, and HI titers by time after transplantation, immunosuppression grade, and cGVHD grade in 43 patients (197 samples in total). Note that data show one-dimensional associations, whereas regression analysis was performed with a high-dimensional model simultaneously accounting for time after transplantation, immunosuppression/cGVHD grade, and correcting for sex and age.